Inotek Names VP of Strategy & IR

Inotek Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, has appointed Claudine Prowse vice president, strategy and investor relations. Dr. Prowse’s responsibilities will include defining corporate strategy to expand business opportunities, corporate communications and investor relations, and interfacing with key external business and investor constituents. She will report directly to David Southwell, president and chief executive officer, and serve as a member of the Inotek management team.

“We are delighted to welcome Claudine to Inotek during this important time for our company. Claudine is a respected biotechnology executive with a strategic mindset and keen sense of the role that science, innovation, and communication play in creating value. I anticipate that her strong blend of scientific understanding and accomplished history working with the financial community will be a significant asset as we work with Inotek’s stakeholders.”

Dr. Prowse has more than 15 years of experience in the biotechnology industry spanning small, mid and large cap biotech companies and previously served as vice president, investor relations at Biogen.

“Inotek is at a key inflection point as we prepare to commence the Phase 3 development program for Trabodenoson,” said Dr. Prowse. “The company has a highly collaborative culture based on a team of executives that have worked together in the past, and a track record of multiple NDA approvals followed by successful launches. I am very excited to join the Inotek team to help formulate and execute the long-term vision for the company.”